Neuroimaging Biomarkers in Schizophrenia
Open accessThe DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Schizophrenia is a complex neuropsychiatric syndrome with a heterogeneous genetic, neurobiological, and phenotypic profile. Currently, no objective biological measures—that is, biomarkers—are available to inform diagnostic or treatment decisions. Neuroimaging is well positioned for biomarker development in schizophrenia, as it may capture phenotypic variations in molecular and cellular disease targets, or in brain circuits. These mechanistically based biomarkers may represent a direct measure of the pathophysiological underpinnings of the disease process and thus could serve as true intermediate or surrogate endpoints. Effective biomarkers could validate new treatment targets or pathways, predict response, aid in selection of patients for therapy, determine treatment regimens, and provide a rationale for personalized treatments. In this review, the authors discuss a range of mechanistically plausible neuroimaging biomarker candidates, including dopamine hyperactivity, N-methyl-d-aspartate receptor hypofunction, hippocampal hyperactivity, immune dysregulation, dysconnectivity, and cortical gray matter volume loss. They then focus on the putative neuroimaging biomarkers for disease risk, diagnosis, target engagement, and treatment response in schizophrenia. Finally, they highlight areas of unmet need and discuss strategies to advance biomarker development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials
the CONSORT Group, Schulz, K. F., Altman, D. G., & Moher, D. (2010) · BMC Medicine · doi:10.1186/1741-7015-8-18 · Cited by 13,371
Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies
Dalmau, J., Gleichman, A. J., Hughes, E. G., Rossi, J. E., Peng, X., Lai, M., Dessain, S. K., Rosenfeld, M. R., Balice-Gordon, R., & Lynch, D. R. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70224-2 · Cited by 3,488
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Toward the future of psychiatric diagnosis: the seven pillars of RDoC
Cuthbert, B. N., & Insel, T. R. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-126 · Cited by 3,053
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
Moghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Glutamate receptor dysfunction and schizophrenia
Olney, J. W. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950240016004 · Cited by 1,685
Decreased Dendritic Spine Density on Prefrontal Cortical Pyramidal Neurons in Schizophrenia
Glantz, L. A., & Lewis, D. A. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.1.65 · Cited by 1,636
The NIMH Research Domain Criteria (RDoC) Project: Precision Medicine for Psychiatry
Insel, T. R. (2014) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2014.14020138 · Cited by 1,472
Predicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
Zhan, Y., Paolicelli, R. C., Sforazzini, F., Weinhard, L., Bolasco, G., Pagani, F., Vyssotski, A. L., Bifone, A., Gozzi, A., Ragozzino, D., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3641 · Cited by 1,236
Kapur, S., Zipursky, R., Jones, C., Remington, G., & Houle, S. (2000) · American Journal of Psychiatry · doi:10.1176/appi.ajp.157.4.514 · Cited by 1,090
Building better biomarkers: brain models in translational neuroimaging
Woo, C.-W., Chang, L. J., Lindquist, M. A., & Wager, T. D. (2017) · Nature Neuroscience · doi:10.1038/nn.4478 · Cited by 1,056
Moghaddam, B., & Javitt, D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.181 · Cited by 1,035
Increased baseline occupancy of D 2 receptors by dopamine in schizophrenia
Abi-Dargham, A., Rodenhiser, J., Printz, D., Zea-Ponce, Y., Gil, R., Kegeles, L. S., Weiss, R., Cooper, T. B., Mann, J. J., Van Heertum, R. L., et al. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.8104 · Cited by 1,020
Thompson, P. M., Vidal, C., Giedd, J. N., Gochman, P., Blumenthal, J., Nicolson, R., Toga, A. W., & Rapoport, J. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.201243998 · Cited by 812
Animal models of schizophrenia
Jones, C., Watson, D., & Fone, K. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01386.x · Cited by 771
Dysconnectivity in schizophrenia: where are we now?
Pettersson-Yeo, W., Allen, P., Benetti, S., McGuire, P., & Mechelli, A. (2011) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2010.11.004 · Cited by 712
Increased Synaptic Dopamine Function in Associative Regions of the Striatum in Schizophrenia
Kegeles, L. S., Abi-Dargham, A., Frankle, W. G., Gil, R., Cooper, T. B., Slifstein, M., Hwang, D.-R., Huang, Y., Haber, S. N., & Laruelle, M. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.10 · Cited by 565
The dysconnection hypothesis (2016)
Friston, K., Brown, H. R., Siemerkus, J., & Stephan, K. E. (2016) · Schizophrenia Research · doi:10.1016/j.schres.2016.07.014 · Cited by 561
Schobel, S. A., Chaudhury, N. H., Khan, U. A., Paniagua, B., Styner, M. A., Asllani, I., Inbar, B. P., Corcoran, C. M., Lieberman, J. A., Moore, H., et al. (2013) · Neuron · doi:10.1016/j.neuron.2013.02.011 · Cited by 549
Glutamate in Schizophrenia: A Focused Review and Meta-Analysis of 1H-MRS Studies
Marsman, A., van den Heuvel, M. P., Klomp, D. W. J., Kahn, R. S., Luijten, P. R., & Hulshoff Pol, H. E. (2013) · Schizophrenia Bulletin · doi:10.1093/schbul/sbr069 · Cited by 457
Disruption of cortical association networks in schizophrenia and psychotic bipolar disorder
Baker, J. T., Holmes, A. J., Masters, G. A., Yeo, B. T. T., Krienen, F., Buckner, R. L., & Öngür, D. (2014) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.3469 · Cited by 435
Jackson, M. E., Homayoun, H., & Moghaddam, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308455101 · Cited by 430
Merritt, K., Egerton, A., Kempton, M. J., Taylor, M. J., & McGuire, P. K. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.0442 · Cited by 367
Steullet, P., Cabungcal, J.-H., Coyle, J., Didriksen, M., Gill, K., Grace, A. A., Hensch, T. K., LaMantia, A.-S., Lindemann, L., Maynard, T. M., et al. (2017) · Molecular Psychiatry · doi:10.1038/mp.2017.47 · Cited by 360
Postmortem evidence of cerebral inflammation in schizophrenia: a systematic review
Trépanier, M. O., Hopperton, K. E., Mizrahi, R., Mechawar, N., & Bazinet, R. P. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.90 · Cited by 360
Hippocampal dysregulation of dopamine system function and the pathophysiology of schizophrenia
Lodge, D. J., & Grace, A. A. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.05.001 · Cited by 349
The search for imaging biomarkers in psychiatric disorders
Abi-Dargham, A., & Horga, G. (2016) · Nature Medicine · doi:10.1038/nm.4190 · Cited by 311
Rowland, L. M., Bustillo, J. R., Mullins, P. G., Jung, R. E., Lenroot, R., Landgraf, E., Barrow, R., Yeo, R., Lauriello, J., & Brooks, W. M. (2005) · American Journal of Psychiatry · doi:10.1176/appi.ajp.162.2.394 · Cited by 304
Mao, X. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1519 · Cited by 296
Stone, J. M., Dietrich, C., Edden, R., Mehta, M. A., De Simoni, S., Reed, L. J., Krystal, J. H., Nutt, D., & Barker, G. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.171 · Cited by 295
Inflammation and the neural diathesis-stress hypothesis of schizophrenia: a reconceptualization
Howes, O. D., & McCutcheon, R. (2017) · Translational Psychiatry · doi:10.1038/tp.2016.278 · Cited by 288
Schizophrenia: More dopamine, more D 2 receptors
Seeman, P., & Kapur, S. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.14.7673 · Cited by 279
GABAergic mechanisms of hippocampal hyperactivity in schizophrenia
Heckers, S., & Konradi, C. (2015) · Schizophrenia Research · doi:10.1016/j.schres.2014.09.041 · Cited by 277
Neurodevelopmental and neurodegenerative models of schizophrenia: white matter at the center stage
Kochunov, P., & Hong, L. E. (2014) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu070 · Cited by 236
Karlsgodt, K. H., Niendam, T. A., Bearden, C. E., & Cannon, T. D. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.03.013 · Cited by 229
Driesen, N. R., McCarthy, G., Bhagwagar, Z., Bloch, M., Calhoun, V, D'Souza, D. C., Gueorguieva, R., He, G., Ramachandran, R., Suckow, R. F., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.194 · Cited by 224
Accelerated Gray and White Matter Deterioration With Age in Schizophrenia
Cropley, V. L., Klauser, P., Lenroot, R. K., Bruggemann, J., Sundram, S., Bousman, C., Pereira, A., Di Biase, M. A., Weickert, T. W., Weickert, C. S., et al. (2017) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2016.16050610 · Cited by 217
Neuroinflammation in schizophrenia: meta-analysis of in vivo microglial imaging studies
Marques, T. R., Ashok, A. H., Pillinger, T., Veronese, M., Turkheimer, F. E., Dazzan, P., Sommer, I. E. C., & Howes, O. D. (2019) · Psychological Medicine · doi:10.1017/s0033291718003057 · Cited by 213
Baseline Striatal Functional Connectivity as a Predictor of Response to Antipsychotic Drug Treatment
Sarpal, D. K., Argyelan, M., Robinson, D. G., Szeszko, P. R., Karlsgodt, K. H., John, M., Weissman, N., Gallego, J. A., Kane, J. M., Lencz, T., et al. (2016) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2015.14121571 · Cited by 212
The Science of Prognosis in Psychiatry: A Review
Fusar-Poli, P., Hijazi, Z., Stahl, D., & Steyerberg, E. W. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.2530 · Cited by 197
Increased Hippocampal Glutamate and Volumetric Deficits in Unmedicated Patients With Schizophrenia
Kraguljac, N. V., White, D. M., Reid, M. A., & Lahti, A. C. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.2437 · Cited by 191
Self-citationJavitt, D. C., Carter, C. S., Krystal, J. H., Kantrowitz, J. T., Girgis, R. R., Kegeles, L. S., Ragland, J. D., Maddock, R. J., Lesh, T. A., Tanase, C., et al. (2018) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2017.3572 · Cited by 100
Bossong, M. G., Antoniades, M., Azis, M., Samson, C., Quinn, B., Bonoldi, I., Modinos, G., Perez, J., Howes, O. D., Stone, J. M., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2018.3252 · Cited by 81
Crum, W. R., Sawiak, S. J., Chege, W., Cooper, J. D., Williams, S. C. R., & Vernon, A. C. (2017) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2016.12.008 · Cited by 76
Cited by
Candidate biomarkers in psychiatric disorders: state of the field
Abi‐Dargham, A., Moeller, S. J., Ali, F., DeLorenzo, C., Domschke, K., Horga, G., Jutla, A., Kotov, R., Paulus, M. P., Rubio, J. M., et al. (2023) · World Psychiatry · doi:10.1002/wps.21078 · Cited by 372
Metadata
- Authors
- Kraguljac, N. V., McDonald, W. M., Widge, A. S., Rodriguez, C. I., Tohen, M., & Nemeroff, C. B.
- Venue
- American Journal of Psychiatry
- Published
- 2021-06
- Volume
- 178
- Issue
- 6
- Pages
- 509-521
- ISSN
- 0002-953X (ISSN-L)
- 1535-7228
- OpenAlex
- W3121061938
- Cited by
- 241
- References
- 46
- FWCI
- 23.80
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.